Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia

2.1 Ibrutinib (Imbruvica, Janssen-Cilag) with venetoclax (Venclyxto, AbbVie) is indicated for 'the treatment of adult patients with previously untreated chronic lymphocytic leukaemia'.

2.2 The dosage schedule is available in the summary of product characteristics for ibrutinib.

2.3 A 28‑pack of 140‑mg ibrutinib tablets costs £1,430.80 (excluding VAT; BNF online accessed February 2022). The company has a commercial arrangement. This makes ibrutinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

2.4 A 112‑pack of 100‑mg venetoclax tablets costs £4,789.47 (excluding VAT; BNF online accessed February 2022). AbbVie has a commercial arrangement. This makes venetoclax available to the NHS with a discount. The size of the discount is commercial in confidence. It is AbbVie's responsibility to let relevant NHS organisations know details of the discount.